News

Boston Scientific said that the Taxus Element Stent System is the company’s third-generation drug-eluting stent (DES) technology and incorporates a platinum chromium alloy with an innovative stent design

As per the terms of the agreement, Danone is expected to pay an amount of approximately $62m in cash to MNI’s shareholders for the acquisition of 100% of

The advisory committee of FDA, that reviews and decides whether to approve a new treatment, has voted that FTY720 demonstrated substantial efficacy in treating relapsing remitting MS and

Benlysta is being developed by GlaxoSmithKline (GSK) and HGS under a co-development and commercialisation agreement entered into in 2006. Benlysta is an investigational human monoclonal antibody drug. Both

WaferGen said that the first panel, SmartChip Human MicroRNA Panel, provides a comprehensive human microRNA profile of more than 800 microRNAs on a single SmartChip and usefull with

Repros is expected to be allowed to run a single study under the new partial clinical hold status. The new low dose study is designed to explore both

FDA granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology. Oxaliplatin injection is therapeutically equivalent to Eloxatin, which is invented and marketed by

Protagen and Bayer Schering Pharma aim to evaluate the UNIarray technology for discovery of autoantibody patterns for the predictive diagnosis of endometriosis. Peter Schulz-Knappe, CSO and executive vice

Orchid is an India-based pharmaceutical company involved in manufacturing, development and marketing of diverse bulk actives, formulation and nutraceuticals. Through this acquisition, Orchid has created its presence in